{
  "ticker": "CSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959015",
  "id": "02959015",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250617",
  "time": "0837",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kt7l1mycw2m9.pdf",
  "summary": "- **FDA Approval**: U.S. FDA approves CSL's ANDEMBRY\u00ae for hereditary angioedema (HAE) prophylaxis, enabling immediate U.S. launch.  \n- **Market Differentiation**: First and only treatment targeting factor XIIa, with once-monthly dosing via autoinjector.  \n- **Efficacy**: Phase 3 trial showed \u226599% median reduction in HAE attacks vs. placebo (89.2% least squares mean reduction).  \n- **Commercialization**: U.S. availability through specialty pharmacies by end-June 2025.  \n- **Global Approvals**: Previously approved in Australia, EU, UK, Japan, Switzerland, and UAE.  \n\n(*Excluded: Trial methodology details, contact information, boilerplate.*)",
  "usage": {
    "prompt_tokens": 868,
    "completion_tokens": 157,
    "total_tokens": 1025,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T22:59:45.967931"
}